PDF icon Download PDF
Kardiologie up2date 2013; 09(01): 37-56
DOI: 10.1055/s-0032-1326192
Herzinsuffizienz
© Georg Thieme Verlag KG Stuttgart · New York

Elektrische Therapie der Herzinsuffizienz

Jürgen Kuschyk
,
Martin Borggrefe
Further Information

Publication History

Publication Date:
28 March 2013 (online)

Also available ateRef
   Permissions and Reprints All articles of this category
Preview

Abstract

Heart failure affects approximately 1 – 2 % of the adult population in developed countries with the prevalence rising to ≥ 10 % among persons 70 years of age or older. Based on optimal medical treatment, additional electrical therapy might be beneficial for selected patients. For symptomatic patients with systolic dysfunction, wide QRS complex and left bundle brunch block Cardiac Resynchronization Therapy has a class I recommendation. For patients with a normal QRS duration Cardiac Contractility Modulation has been proven to be effective. Recently, there is raising attention on autonomous modulation for heart failure to restore sympathetic-parasympathetic balance.

Kernaussagen

  • Die symptomatische Herzinsuffizienz ist die führende Todesursache und einer der Hauptgründe für Hospitalisierungen in der westlichen Welt mit weitreichenden sozioökonomischen Implikationen.

  • Die Basistherapie besteht in der leitliniengerechten medikamentösen Therapie. Bei weiterhin symptomatischen Patienten können Device-basierte elektrische Therapieverfahren in Betracht gezogen werden.

  • Für Patienten mit verbreitertem QRS-Komplex und idealerweise Linksschenkelblock hat die CRT eine Klasse-I-Indikation, allerdings erfüllen nur ca. 30 % der Patienten diese Kriterien. Die klinische Erfolgsrate liegt bei ca. 50 – 70 %.

  • Für Patienten mit schmalem bis mäßig verbreitertem QRS-Komplex ist die kardiale Kontraktilitätsmodulation (CCM) eine Therapieoption. Durch hochenergetische Signalabgabe während der absoluten Refraktärphase kann es über komplexe Interaktionen der am Kalziumhaushalt beteiligten Schlüsselproteine zu einer akuten und chronischen Kontraktilitätssteigerung kommen.

  • Bisher nur im Rahmen von Studien untersucht sind Methoden der autonomen Modulation. Zugrunde liegt das pathophysiologische Korrelat einer sympathisch-parasympathischen Dysregulation bei Herzinsuffizienz mit den Folgen einer erhöhten Mortalität. Mit unterschiedlichen Stimulationsmethoden kann an variablen Stellen des autonomen Nervensystems diese Dysbalance ausgeglichen werden. Mögliche Therapieoptionen sind die Vagusstimulation, Spinal Cord Stimulation oder Barorezeptor-Aktivierungs-Therapie. Der klinische Stellenwert der Modulationstherapie kann vor Abschuss laufender Studien noch nicht abschließend bewertet werden. Für die Vagusstimulation liegen Ergebnisse einer Pilotstudie vor mit nachgewiesener Verbesserung funktioneller und linksventrikulärer Parameter, der Lebensqualität sowie der Belastungskapazität.

 

  • Literatur

  • 1 Daubert JC, Saxon L, Adamson PB et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2012; 14: 1236-1286
    PubMedSearch in Google Scholar
  • 2 Dickstein K, Vardas PE, Auricchio A et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010; 31: 2677-2687
    CrossrefPubMedSearch in Google Scholar
  • 3 Israel CW, Anker SD, Hasenfuss G. Commentary on the 2010 ESC guidelines on device therapy in heart failure. Herzschrittmachertherapie & Elektrophysiologie 2012; 23: 33-37
    PubMedSearch in Google Scholar
  • 4 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
    CrossrefPubMedSearch in Google Scholar
  • 5 Tracy CM, Epstein AE, Darbar D et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 1297-1313
    CrossrefPubMedSearch in Google Scholar
  • 6 Dupont M, Rickard J, Baranowski B et al. Differential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. J Am Coll Cardiol 2012; 60: 592-598
    CrossrefPubMedSearch in Google Scholar
  • 7 Gold MR, Thebault C, Linde C et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012; 126: 822-829
    CrossrefPubMedSearch in Google Scholar
  • 8 Hara H, Oyenuga OA, Tanaka H et al. The relationship of QRS morphology and mechanical dyssynchrony to long-term outcome following cardiac resynchronization therapy. Eur Heart J 2012; 33: 2680-2691
    CrossrefPubMedSearch in Google Scholar
  • 9 Singh JP, Klein HU, Huang DT et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011; 123: 1159-1166
    CrossrefPubMedSearch in Google Scholar
  • 10 Gold MR, Birgersdotter-Green U, Singh JP et al. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J 2011; 32: 2516-2524
    CrossrefPubMedSearch in Google Scholar
  • 11 Exner DV, Auricchio A, Singh JP. Contemporary and future trends in cardiac resynchronization therapy to enhance response. Heart rhythm: the official journal of the Heart Rhythm Society 2012; 9: 27-35
    PubMedSearch in Google Scholar
  • 12 Eitel C, Doring M, Gaspar T et al. Cardiac resynchronization therapy with individualized placement of two left ventricular leads at the sites of latest mechanical left ventricular contraction: guided by 3D-echocardiography and coronary sinus rotation angiography. Eur J of heart failure 2010; 12: 411-414
    PubMedSearch in Google Scholar
  • 13 Arias MA, Pachon M, Puchol A et al. Acute and mid-term outcomes of transvenous implant of a new left ventricular quadripolar lead versus bipolar leads for cardiac resynchronization therapy: results from a single-center prospective database. Cardiology journal 2012; 19: 470-478
    CrossrefPubMedSearch in Google Scholar
  • 14 Borggrefe MM, Lawo T, Butter C et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008; 29: 1019-1028
    CrossrefPubMedSearch in Google Scholar
  • 15 Kadish A, Nademanee K, Volosin K et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011; 161: 329-337 e1-2
    CrossrefPubMedSearch in Google Scholar
  • 16 Abraham WT, Nademanee K, Volosin K et al. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Journal of cardiac failure 2011; 17: 710-717
    CrossrefPubMedSearch in Google Scholar
  • 17 Nagele H, Behrens S, Eisermann C. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2008; 10: 1375-1380
    PubMedSearch in Google Scholar
  • 18 Bilgutay AM, Bilgutay IM, Merkel FK et al. Vagal tuning. A new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure. Journal of thoracic and cardiovascular surgery 1968; 56: 71-82
    PubMedSearch in Google Scholar
  • 19 La Rovere MT, Bigger Jr JT, Marcus FI et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-484
    CrossrefPubMedSearch in Google Scholar
  • 20 Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428-1433
    CrossrefPubMedSearch in Google Scholar
  • 21 Olshansky B, Sabbah HN, Hauptman PJ et al. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008; 118: 863-871
    CrossrefPubMedSearch in Google Scholar
  • 22 Milby AH, Halpern CH, Baltuch GH. Vagus nerve stimulation for epilepsy and depression. Neurotherapeutics: journal of the American Society for Experimental NeuroTherapeutics 2008; 5: 75-85
    PubMedSearch in Google Scholar
  • 23 Schwartz PJ, De Ferrari GM, Sanzo A et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J of heart failure 2008; 10: 884-891
    PubMedSearch in Google Scholar
  • 24 De Ferrari GM, Crijns HJ, Borggrefe M et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011; 32: 847-855
    CrossrefPubMedSearch in Google Scholar
  • 25 Kuschyk J, Borggrefe M. Vagus stimulation. Mechanisms and current clinical importance in heart failure. Herzschrittmachertherapie & Elektrophysiologie 2011; 22: 21-26
    PubMedSearch in Google Scholar
  • 26 Hauptman PJ, Schwartz PJ, Gold MR et al. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J 2012; 163: 954-962
    CrossrefPubMedSearch in Google Scholar
  • 27 Bisognano JD, Bakris G, Nadim MK et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-773
    CrossrefPubMedSearch in Google Scholar
  • 28 Liu Y, Yue WS, Liao SY et al. Thoracic spinal cord stimulation improves cardiac contractile function and myocardial oxygen consumption in a porcine model of ischemic heart failure. Journal of cardiovascular electrophysiology 2012; 23: 534-540
    CrossrefPubMedSearch in Google Scholar
  • 29 Issa ZF, Zhou X, Ujhelyi MR et al. Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmias in a postinfarction heart failure canine model. Circulation 2005; 111: 3217-3220
    CrossrefPubMedSearch in Google Scholar
  • 30 Cameron T. Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: a 20-year literature review. Journal of neurosurgery 2004; 100: 254-267
    PubMedSearch in Google Scholar